Mortality and length of hospital stay after bloodstream infections caused by ESBL-producing compared to non-ESBL-producing E. coli

被引:5
|
作者
Handal, Nina [1 ]
Whitworth, Jimmy [2 ]
Lyngbakken, Magnus Nakrem [3 ,4 ]
Berdal, Jan Erik [3 ,4 ]
Dalgard, Olav [3 ,4 ]
Jorgensen, Silje Bakken [1 ,5 ]
机构
[1] Akershus Univ Hosp, Dept Microbiol & Infect Control, Div Diagnost & Technol, Lorenskog, Norway
[2] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England
[3] Akershus Univ Hosp, Dept Infect Dis, Div Med, Lorenskog, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
[5] Akershus Univ Hosp, Dept Emergency Med, Div Internal Med, Lorenskog, Norway
关键词
Extended-spectrum beta-lactamases (ESBL); bloodstream infection; mortality; Enterobacterales; antimicrobial resistance; healthcare associated infection; LACTAMASE-PRODUCING ENTEROBACTERIACEAE; ESCHERICHIA-COLI; BACTEREMIA; OUTCOMES; EPIDEMIOLOGY; VALIDATION; RESISTANCE; THERAPY;
D O I
10.1080/23744235.2023.2261538
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To compare mortality and length of hospital stay between patients with ESBL-producing E. coli bloodstream infections (BSIs) and patients with non-ESBL E. coli BSIs. We also aimed at describing risk factors for ESBL-producing E. coli BSIs and time to effective antibiotic treatment for the two groups.Methods: A retrospective case-control study among adults admitted between 2014 and 2021 to a Norwegian University Hospital.Results: A total of 468 E. coli BSI episodes from 441 patients were included (234 BSIs each in the ESBL- and non-ESBL group). Among the ESBL-producing E. coli BSIs, 10.9% (25/230) deaths occurred within 30 days compared to 9.0% (21/234) in the non-ESBL group. The adjusted 30-day mortality OR was 1.6 (95% CI 0.7-3.7, p = 0.248). Effective antibiotic treatment was administered within 24 hours to 55.2% (129/234) in the ESBL-group compared to 86.8% (203/234) in the non-ESBL group. Among BSIs of urinary tract origin (n = 317), the median length of hospital stay increased by two days in the ESBL group (six versus four days, p < 0.001). No significant difference in the length of hospital stay was found for other sources of infection (n = 151), with a median of seven versus six days (p = 0.550) in the ESBL- and non-ESBL groups, respectively.Conclusion: There was no statistically significant difference in 30-day mortality in ESBL-producing E. coli compared to non-ESBL E. coli BSI, despite a delay in the administration of an effective antibiotic in the former group. ESBL-production was associated with an increased length of stay in BSIs of urinary tract origin.
引用
收藏
页码:19 / 31
页数:13
相关论文
共 50 条
  • [21] Epidemiological factors associated with ESBL- and non ESBL-producing E. coli causing urinary tract infection in general practice
    Hertz, Frederik Boetius
    Schonning, Kristian
    Rasmussen, Steen Christian
    Littauer, Pia
    Knudsen, Jenny Dahl
    Lobner-Olesen, Anders
    Frimodt-Moller, Niels
    INFECTIOUS DISEASES, 2016, 48 (03) : 241 - 245
  • [22] Distribution, Numbers, and Diversity of ESBL-Producing E. coli in the Poultry Farm Environment
    Blaak, Hetty
    van Hoek, Angela H. A. M.
    Hamidjaja, Raditijo A.
    van der Plaats, Rozemarijn Q. J.
    Kerkhof-de Heer, Lianne
    Husman, Ana Maria de Roda
    Schets, Franciska M.
    PLOS ONE, 2015, 10 (08):
  • [23] Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae
    Bitsori, Maria
    Galanakis, Emmanouil
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (12) : E332 - E335
  • [24] Characterization of qnrB-carrying plasmids from ESBL- and non-ESBL-producing Escherichia coli
    Katharina Juraschek
    Janina Malekzadah
    Burkhard Malorny
    Annemarie Käsbohrer
    Stefan Schwarz
    Diana Meemken
    Jens Andre Hammerl
    BMC Genomics, 23
  • [25] Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria
    Russo, Alessandro
    Berruti, Marco
    Giacobbe, Daniele Roberto
    Vena, Antonio
    Bassetti, Matteo
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (08) : 983 - 991
  • [26] Multidrug-Resistant ESBL-Producing E. coli in Clinical Samples from the UK
    Ibrahim, Delveen R.
    Dodd, Christine E. R.
    Stekel, Dov J.
    Meshioye, Remilekun T.
    Diggle, Mathew
    Lister, Michelle
    Hobman, Jon L.
    ANTIBIOTICS-BASEL, 2023, 12 (01):
  • [27] Characterization of qnrB-carrying plasmids from ESBL- and non-ESBL-producing Escherichia coli
    Juraschek, Katharina
    Malekzadah, Janina
    Malorny, Burkhard
    Kaesbohrer, Annemarie
    Schwarz, Stefan
    Meemken, Diana
    Hammerl, Jens Andre
    BMC GENOMICS, 2022, 23 (01)
  • [28] High Emergence of ESBL-Producing E. coli Cystitis: Time to Get Smarter in Cyprus
    Cantas, Leon
    Suer, Kaya
    Guler, Emrah
    Imir, Turgut
    FRONTIERS IN MICROBIOLOGY, 2016, 6
  • [29] Re: Comparison of Host Response Mechanisms Evoked by Extended Spectrum Beta Lactamase (ESBL)-and Non-ESBL-Producing Uropathogenic E. coli Editorial Comment
    Schaeffer, Edward M.
    JOURNAL OF UROLOGY, 2014, 192 (06): : 1693 - 1693
  • [30] Genotypic characterization of ESBL-producing E. coli from imported meat in South Korea
    Kim, Young-Jo
    Moon, Jin-San
    Oh, Deog-Hwan
    Chon, Jung-Whan
    Song, Bo-Ra
    Lim, Jong-Su
    Heo, Eun-Jeong
    Park, Hyun-Jung
    Wee, Sung-Hwan
    Sung, Kidon
    FOOD RESEARCH INTERNATIONAL, 2018, 107 : 158 - 164